Advances in Neurofibromatosis in Children, Adolescents, and Young Adults
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 1 June 2026 | Viewed by 1197
Special Issue Editors
Interests: patient reported outcomes; neurocognitive outcomes; quality of life; psychosocial well-being; survivorship; late effects; behavioral health interventions; pediatric brain tumors; pediatric cancer predisposition syndromes; pediatric ALL
Interests: pediatric oncology; neurofibromatosis; clinical trial design
2. Nemours Children's Hospital, Delaware 1600 Rockland Road, Wilmington, DE 19803, USA
Interests: neurofibromatosis; MPNST; genomics; cell free DNA; proteomics; epigenetics; liquid biopsy; peripheral nerve sheath tumors
Special Issue Information
Dear Colleagues,
Neurofibromatosis type 1 (NF1), NF2-related schwannomatosis (NF2), and non-NF2-related schwannomatosis (SWN) are rare genetic tumor predisposition syndromes in which various types of tumor may develop in the central and peripheral nervous systems. Individuals with these conditions also may experience various non-tumor-related phenotypes that may arise in childhood, such as juvenile cataracts in NF2 and bone abnormalities and cognitive impairments in NF1. This Special Issue will focus on all types of research focusing on children, adolescents, and young adults with NF1, NF2, or SWN. Manuscripts should describe interventional trials, the development of novel assessment tools, and results from natural history studies for these genetic conditions. Such studies are needed to evaluate new drug treatments or behavioral interventions, to better understand the development of both benign and malignant tumors and other clinical manifestations (e.g., bone, neurologic, cognitive, and social–emotional issues, pain, hearing loss, and physical problems), to investigate the underlying mechanism related to the pathology of these manifestations, and to develop new patient-centered outcomes and biomarkers to monitor changes over time related to these disorders and with treatment specifically focused on children, adolescents, and young adults. Studies that are exclusively bioinformatic, such as those that identify candidate biomarkers, will require rigorous cross-validation and, when possible, should be validated in an independent dataset. Additional clinical validation in patient samples and/or functional validation in vitro or in vivo is strongly encouraged.
Dr. Pamela L. Wolters
Dr. Andrea M. Gross
Dr. Russell Taylor Sundby
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neurofibromatosis
- schwannomatosis
- natural history
- clinical trials
- targeted therapy
- outcomes
- psychosocial
- biomarkers
- pediatric
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
